Latest news with #N-Dimethyltryptamine
Sunday World
17 hours ago
- Sunday World
Woman (38) caught with over €4k worth of drugs including an ‘exotic substance'
Defence barrister, Mr Garnet Orange, SC said at the time of the offence, Candice Faulkner Faulkner was an advocate for the cannabis use. A Donegal woman has appeared in court after being caught with over €4,000 worth of drugs, including an 'exotic substance.' Candice Faulkner (38) of Marion Park, Buncrana appeared at Letterkenny Circuit Court before Judge John Aylmer charged with drugs offences. She is charged with possession of a controlled drug, namely cannabis, for unlawful sale or supply at Marion Park on December 28, 2020. Additionally, she is also charged with possessing cannabis resin for the purpose of unlawful sale or supply to another on the same date and location. Faulkner is also charged with possessing N,N-Dimethyltryptamine for the purpose of unlawful sale or supply to another on the same date and location. Garda Declan O'Brien and State Prosecutor Fiona Crawford BL outlined the details of the case and said a search warrant was obtained to search Faulkner's property in December 2020. Faulkner was not present at the time of the search on December 28, 2020 but she returned to the house while the gardaí were there. Candice Faulkner. Photo: Northwest News Pix News in 90 Seconds - 7th June The court heard that cannabis, cannabis resin and N,N-Dimethyltryptamine (N N DMT) were found at the property. Faulkner made full admissions to owning the cannabis while scales, jars and various other items were also found in the property. The court heard Faulkner had previous convictions but they related to traffic matters. Defence barrister, Mr Garnet Orange, SC said at the time of the offence, Faulkner was an advocate for the cannabis use. The cannabis found was 87.7 grams valued at €1,754 while the 289grams of cannabis resin was valued at €1,735.80. However, the court heard it was difficult to put a value on the other plant material but it was valued at €620. In relation to the N,N-Dimethyltryptamine (N N DMT), the court heard a 'strange' red bark material and is a hallucinogenic. Mr Orange referred to the substance as 'eye catching' and an 'exotic substance'. He added there was a difficulty in identifying what it was and placing an evaluation on the substance. Mr Orange said when Faulkner was asked about the substance, she 'didn't have a clue about it' and he said it was found on top of the wardrobe and was covered in dust. The court heard there was a process to distil the hallucinogenic and there was no evidence to suggest that this process was carried out. Mr Orange said Faulkner is a long time cannabis user who uses it in the context of ADHD and she is not out selling drugs on the street. He said the emphasis should be on supply rather than sale. Judge John Aylmer questioned about the other items found at the house and Mr Orange said Faulkner would measure out her own consumption before use and the drugs were for personal use while she also denies that a tick list had anything to do with her. The court heard Faulkner is keen to stop using and is no longer an advocate for cannabis use. Mr Orange asked Judge John Aylmer to deal with the case by a suspended sentence and asked for a probation report to be completed on his client. Judge John Aylmer approved the request for a probation report and ordered it to include an assessment for suitability for community service. The case was adjourned to the October session of the Letterkenny Circuit Court.
Associated Press
17-03-2025
- Business
- Associated Press
Enveric Biosciences Participating in BIO-Europe Spring®
Enveric Biosciences, Inc. (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its participation in BIO-Europe Spring ®, which is being held in Milan, Italy, March 17-19, 2025. During the Spring partnering event, members of Enveric's management team are conducting one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones. 'We anticipate a highly productive meeting at BIO-Europe Spring as we continue to garner interest in our strategic approach to developing neuroplastogenic molecules, led by EB-003, for the treatment of underserved mental health conditions. Our ongoing discussions with leaders in the pharmaceutical industry clearly indicate that eliminating or substantially reducing the hallucinatory effect common to N,N-Dimethyltryptamine (DMT), mescaline and related analogs will be key to commercial success,' said Joseph Tucker, Ph.D., Director and Chief Executive Officer of Enveric. About Enveric Biosciences Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, the Psybrary™, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing all other novel, patented Psybrary™ drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Tiberend Strategic Advisors, Inc. David Irish (231) 632-0002 [email protected] Relations Tiberend Strategic Advisors, Inc. Casey McDonald (646) 577-8520 INDUSTRY KEYWORD: MENTAL HEALTH HEALTH GENERAL HEALTH RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Enveric Biosciences, Inc. Copyright Business Wire 2025. PUB: 03/17/2025 01:40 PM/DISC: 03/17/2025 01:40 PM
Yahoo
14-03-2025
- Business
- Yahoo
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
In this week's 'Psychedelic,' The Fly's recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement. Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. ATAI DOSES FIRST PATIENT IN PHASE 2 VLS-01 TRIAL: atai Life Sciences (ATAI) announced Tuesday that the first patient has been dosed in the Phase 2 Elumina trial of VLS-01, atai's proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine applied to the buccal surface, in people suffering from treatment-resistant depression. 'Dosing the first patient in the Phase 2 Elumina trial of VLS-01 marks a significant milestone in our commitment to transforming the treatment landscape for mental health disorders,' stated Kevin Craig, CEO. 'Millions worldwide struggle with treatment-resistant depression, often left with few or no viable options. With VLS-01, we see the potential to offer rapid, robust, and durable antidepressant effects that could provide meaningful relief where existing treatments fall short. This trial brings us one step closer to delivering a new and innovative solution to those people who need it most.' Elumina is a Phase 2, multi-center, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of repeated doses of VLS-01. The trial consists of two treatment periods. In the first treatment period, approximately 142 patients will be randomized 1:1 to receive a 120mg dose of VLS-01 or placebo on Day 1, followed by a second dose of the same intervention at Week 2. The primary endpoint is the change from Baseline in Montgomery-Asberg Depression Rating Scale total score at Week 4. The last double-blind assessment visit will be at Week 14. The first treatment period will provide 12 weeks of blinded durability data following two doses of VLS-01 administered in a placebo-controlled fashion. Topline results from the first treatment period are anticipated in 1Q26. MIRA EXPANDS KETAMIR-2 DEVELOPMENT WITH TOPICAL: On Thursday, MIRA Pharmaceuticals (MIRA) announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This expands the company's pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief. The topical treatment of Ketamir-2 is designed for slow release, delivering targeted pain relief directly at the application site while minimizing systemic exposure and side effects. 'The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA,' stated Erez Aminov, CEO . 'By advancing two distinct formulations, we are positioning Ketamir-2 to address multiple pain conditions and broaden its potential applications. This strategic approach strengthens our presence in the pain management space and underscores our commitment to delivering innovative solutions while creating value for our shareholders.' PHARMALA SIGNS DISTRIBUTOR IN THE NETHERLANDS: PharmAla Biotech Holdings (MDXXF) announced Monday that it has signed a distribution agreement with Duchefa Farma of Haarlem, Netherlands, to act as exclusive distribution agent for its LaNeo MDMA in the Netherlands market. The distribution agreement includes an annual purchase minimum, as well as restrictions on re-export and price controls. It also includes an escalator provision which would significantly increase the minimum purchase amounts in the 24 months following regulatory changes which allow for use of MDMA in the healthcare system. Duchefa will also act as Importer of Record as well as providing Qualified Person Release of PharmAla's products. 'We are confident that this deal will open significant new opportunities for both Duchefa and PharmAla. This is the first new market we have officially opened since entering Australia in late 2023,' said Nick Kadysh, CEO. 'In looking for a partner we can rely on, we were pleased to see that Duchefa has not only an incredible presence in the Netherlands, but exceptional relationships with partners from the Galenos Group across Europe. We are excited to fulfill the demand for clinical trial materials in the Netherlands, and to assist in pushing the Government of the Netherlands towards greater acceptance of MDMA-Assisted Therapy for the treatment of PTSD.' CLEARMIND ANNOUNCES PATENT PUBLICATION: On Monday, Clearmind Medicine (CMND) announced the publication of a patent by the Korean Intellectual Property Office. The patent covers the company's combination therapy of MEAI and N-Acylethanolamines for the treatment of cocaine addiction. The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University in Israel. These studies build upon earlier experiments in which animals treated with MEAI exhibited a significant reduction in cocaine-induced cravings. Further research was conducted in rats to assess whether MEAI's effects on drug-seeking behavior extended to natural rewards, given that reward-based reinforcement is a fundamental survival mechanism across species. The study produced positive results, demonstrating that while MEAI reduced cocaine-seeking behavior, it did not impair the rats' response to natural rewards such as sucrose. This finding suggests that MEAI's impact on drug cravings is not tied to the general reward system but is specifically targeted at drug-related compulsions. ANALYST STARTS PSYCHEDELIC FIRMS WITH BUYS: Guggenheim initiated coverage of Cybin (CYBN) on Wednesday with a Buy rating and $35 price target. The firm's investment thesis is based on CYB003's robust and durable antidepressant efficacy in Phase 2 major depressive disorder trials and its potential to replicate those data and deliver best-in-class data in Phase 3, the analyst said. The firm believes upside optionality remains, and with multiple key data readouts expected across the space in the next 6-12 months, it thinks now is the time for investors to start paying attention. Guggenheim initiated coverage of GH Research (GHRS) with a Buy rating and $32 price target. The firm's thesis on GH is based around the belief that rapid-acting psychedelics like 5-MeO-DMT have the potential to transform the treatment resistant depression treatment landscape, the analyst said. The firm added that, with pivotal milestones in the sector coming over the next 6-12 months and an update on the clinical hold anticipated this year, it believes GH is well-positioned for long-term upside. OTHER PSYCHEDELIC STOCKS: Publicly-traded companies in the space include Algernon Pharmaceuticals (AGNPF), Allied Corp. (ALID), BetterLife (BETRF), Bright Minds Biosciences (DRUG), Compass Pathways (CMPS), Entheon Biomedical (ENTBF), Enveric Biosciences (ENVB), Filament Health (FLHLF), Incannex Healthcare (IXHL), Mind Medicine (MNMD), Mydecine Innovations (MYCOF), NRx Pharmaceuticals (NRXP), Numinus Wellness (NUMIF), Optimi Health (OPTHF), Pasithea Therapeutics (KTTA), PharmaTher (PHRRF), Psyence Biomedical (PBM), Psyence Group (PSYGF), Quantum BioPharma (QNTM), Relmada Therapeutics (RLMD), Revive Therapeutics (RVVTF), SciSparc (SPRC), Seelos Therapeutics (SEEL), Silo Pharma (SILO) and Synaptogenix (SNPX). Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on ATAI: Questions or Comments about the article? Write to editor@ Largest borrow rate increases among liquid names Atai Life Sciences announces first patient dosed in Elumina Phase 2 trial Psychedelic: MindMed reports Q4 earnings results Atai Life Sciences completes enrollment of Phase 2b trial of BPL-003 Psychedelic: GH Research, Compass Pathways report earnings results Sign in to access your portfolio
